Worrisome ‘right to try’ legislation may soon become law. Here’s the story that some news outlets missed
FDA announces action against two stem cell clinics: Is that a ‘crackdown’?
Fact-checking pharma: 5 cancer drug myths, busted
Approval of ‘breakthrough’ hepatitis C drugs isn’t even half the story; now come the harms
Whitewashing a black box warning: The Chantix story that didn’t get told
With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line
Off-label drug marketing: Who will decide what’s “truthful” when the evidence can’t be trusted?
Early report card on quality of FDA news releases: C at best
Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation
What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups